The Open Window of opportunity study midterm results to be announced by end of year along with guidance for initiation of pivotal phase 3 registration study that will probably be initiated mid 2020 with cash equity associated with phase 3 initiation milestone. Then my best guess is a six months to a year for study completion and another 3-6 months for approval.
The current cash balance of about 12-14 million might be enough cash to keep things running until the cash payment associated with phase 3 initiation. But part of me thinks the company might have one more equity raising event between now and next july.
Given the late stage nature and the broad use of the REOLYSIN treatment and the intellectual property of the company patents, I also think this is undervalued. The recent clinical trial sponsored in part by pfizer may corroborate this.
Part of me expects to see another licensing agreement for some major countries that will give the company upfront cash and milestone equity payments. This could allow the company to forgo anymore dilutionary capital raising events,and if it is done correctly will allow the company enough equity to transition into a commercial biotech company selling treatments starting by as early as first half 2021 and maybe as late as about EOY 2021 or early 2022.
Therefore I am investing at these levels due to the undervalued nature of the stock and with the idea that in the next year there will be plenty of things to move this stock up one of them being a high probability of a licensing agreement, partnership, or buyout, with a major pharmaceutical company. Looking to hold for at least 1 year.
News 
Market Data 
Discover 
